1. Posterior hippocampal sparing in Lewy body disorders with Alzheimer’s copathology: An in vivo MRI study
- Author
-
Jesse S. Cohen, Jeffrey Phillips, Sandhitsu R. Das, Christopher A. Olm, Hamsanandini Radhakrishnan, Emma Rhodes, Katheryn A.Q. Cousins, Sharon X. Xie, Ilya M. Nasrallah, Paul A. Yushkevich, David A. Wolk, Edward B. Lee, Daniel Weintraub, David J. Irwin, and Corey T. McMillan
- Subjects
Lewy body disease ,Parkinson disease ,Magnetic resonance imaging ,Hippocampus ,Alzheimer’s disease ,Dementia ,Computer applications to medicine. Medical informatics ,R858-859.7 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Background: Lewy body disorders (LBD), encompassing Parkinson disease (PD), PD dementia (PDD), and dementia with Lewy bodies (DLB), are characterized by alpha-synuclein pathology but often are accompanied by Alzheimer’s disease (AD) neuropathological change (ADNC). The medial temporal lobe (MTL) is a primary locus of tau accumulation and associated neurodegeneration in AD. However, it is unclear the extent to which AD copathology in LBD (LBD/AD+) contributes to MTL-specific patterns of degeneration. We employ a MTL subregional segmentation strategy of T1-weighted (T1w) MRI in biomarker-supported or autopsy-confirmed LBD and LBD/AD+ to investigate the anatomic consequences of co-occurring LBD/AD+ pathology on neurodegeneration. Methods: We studied 167 individuals with clinical diagnoses of LBD (PD, n = 124 (74.3 %); PDD, n = 11 (6.6 %); DLB, n = 32 (19.2 %)) with available T1w MRI and AD biomarkers or autopsy evidence of ADNC. Individuals were further biologically classified as LBD/AD+ based on hierarchical evidence of ADNC pathology: 1) AD “intermediate” or “high” by ABC neuropathologic criteria (n = 39 (23.4 %)); 2) positive amyloid PET (n = 2 (1.2 %)); or 3) CSF β-amyloid1-42
- Published
- 2025
- Full Text
- View/download PDF